Advertisement

Topics

PubMed Journals Articles About "Identifying Molecular Structure Alzheimer Stickier Culprits" RSS

18:22 EDT 15th July 2019 | BioPortfolio

Identifying Molecular Structure Alzheimer Stickier Culprits PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Identifying Molecular Structure Alzheimer Stickier Culprits articles that have been published worldwide.

More Information about "Identifying Molecular Structure Alzheimer Stickier Culprits" on BioPortfolio

We have published hundreds of Identifying Molecular Structure Alzheimer Stickier Culprits news stories on BioPortfolio along with dozens of Identifying Molecular Structure Alzheimer Stickier Culprits Clinical Trials and PubMed Articles about Identifying Molecular Structure Alzheimer Stickier Culprits for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Identifying Molecular Structure Alzheimer Stickier Culprits Companies in our database. You can also find out about relevant Identifying Molecular Structure Alzheimer Stickier Culprits Drugs and Medications on this site too.

Showing "Identifying molecular structure Alzheimer stickier culprits" PubMed Articles 1–25 of 29,000+

Search for biomarkers of Alzheimer's disease: Recent insights, current challenges and future prospects.

Due to the trend of prolonged lifespan leading to higher incidence of age-related diseases, the demand for reliable biomarkers of dementia rises. In this review, we present novel biomarkers of high potential, especially those found in blood, urine or saliva, which could lead to a more comfortable patient experience and better time- and cost-effectivity, compared to the currently used diagnostic methods. We focus on biomarkers that might allow for the detection of Alzheimer's disease before its clinical mani...


Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer's disease.

The ADAM10-mediated cleavage of transmembrane proteins regulates cellular processes such as proliferation or migration. Substrate cleavage by ADAM10 has also been implicated in pathological situations such as cancer or Morbus Alzheimer. Therefore, identifying endogenous molecules, which modulate the amount and consequently the activity of ADAM10, might contribute to a deeper understanding of the enzyme's role in both, physiology and pathology.

An update on the interactions between Alzheimer's disease, autophagy and inflammation.

An update on pathogenesis of Alzheimer's disease, the present document describes the crosstalk between autophagy and inflammation in Alzheimer's disease progression by assessing key findings and identifying gaps in the current knowledge. Inflammation mediators can disrupt the clearance of misfolded proteins. It is well defined that misfolded protein accumulation and aberrant level of inflammatory mediators in the brain can trigger Alzheimer's disease. Studies indicated that restoring the inflammatory and au...


GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies.

Recruitment for Alzheimer's disease (AD) prevention research studies is challenging because of lack of awareness among cognitively healthy adults coupled with the high screen fail rate due to participants not having a genetic risk factor or biomarker evidence of the disease. Participant recruitment registries offer one solution for efficiently and effectively identifying, characterizing, and connecting potential eligible volunteers to studies.

The Effectiveness of Vitamin E Treatment in Alzheimer's Disease.

Vitamin E was proposed as treatment for Alzheimer's disease many years ago. However, the effectiveness of the drug is not clear. Vitamin E is an antioxidant and neuroprotector and it has anti-inflammatory and hypocholesterolemic properties, driving to its importance for brain health. Moreover, the levels of vitamin E in Alzheimer's disease patients are lower than in non-demented controls. Thus, vitamin E could be a good candidate to have beneficial effects against Alzheimer's. However, evidence is consisten...

Genetic risk for Alzheimer's disease is distinct from genetic risk for amyloid deposition.

Alzheimer's disease (AD) is the most common form of dementia and is responsible for a huge and growing health care burden in the developed and developing world. The Polygenic Risk Score (PRS) approach has shown 75%-84% prediction accuracy of identifying individuals with AD risk.

Tri-Stable Structural Switching in 2D Molecular Assembly at the Liquid/Solid Interface Triggered by External Electric Field.

A tri-stable structural switching between different polymorphisms is presented in 2D molecular assembly of 5-(benzyloxy)-isophthalic acid derivative (BIC-C12) at the liquid/solid interface. The assembled structure of BIC-C12 is sensitive to the applied voltage between the STM tip and the sample surface. A compact lamellar structure is exclusively observed at positive sample bias, while a porous honeycomb structure or a quadrangular structure is preferred at negative sample bias. Selective switching between ...

Identifying Molecular Markers of Cervical Cancer Based on Competing Endogenous RNA Network Analysis.

Recurrence being a major challenge for the treatment of cervical cancer, we aimed at identifying novel molecular markers of cervical cancer to improve recurrence prediction.

Identify compounds's target against Alzheimer's disease based on silico approach.

Alzheimer's disease swept every corner of the globe and the number of patients worldwide has been rising. At present, there are as many as 30 million people with Alzheimer's disease in the world, and it is expected to exceed 80 million people by 2050. Consequently, the study of Alzheimer's drugs has become one of the most popular medical topics.

Human Glutaminyl Cyclase: Structure, Function, Inhibitors and Involvement in Alzheimer's Disease.

Human glutaminyl cyclase (hQC) is an important enzyme for post-translational modification by converting the N-terminal glutaminyl and glutamyl into its pyroglutamate (pGlu) through cyclization. The two isoforms of hQC, secretory glutaminyl cyclase (sQC) and golgi resident glutaminyl cyclase (gQC), are involved in various pathological conditions especially in Alzheimer's disease (AD). The sQC is known to mediate the formation of pyroglutamate containing amyloid beta (pGlu-Aβ) peptides while gQC mediates the...

Molecular docking, molecular dynamics simulations and QSAR studies on some of 2-arylethenylquinoline derivatives for inhibition of Alzheimer's amyloid-beta aggregation: Insight into mechanism of interactions and parameters for design of new inhibitors.

Alzheimer's disease is characterized using amyloid-beta (Aβ) aggregation. The present work was carried out to extend and design a novel quantitative structure-activity relationship (QSAR) model on inhibition efficiency of some of new 2-arylethenylquinoline derivatives against the Aβ peptide aggregation. The QSAR study, molecular docking and molecular dynamics (MD) simulations were performed to explore the influence of the structural features and investigate the molecular mechanism of ligands interactions ...

Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.

Alzheimer's disease (AD) is characterized by amyloid plaques and tau pathology (neurofibrillary tangles and neuropil threads). Amyloid plaques are primarily composed of aggregated and oligomeric β-amyloid (Aβ) peptides ending at position 42 (Aβ42). The development of fluid and PET biomarkers for Alzheimer's disease (AD), has allowed for detection of Aβ pathology in vivo and marks a major advancement in understanding the role of Aβ in Alzheimer's disease (AD). In the recent National Institute on Aging a...

Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is F FDG a specific biomarker in these patients?

The present study was conducted to compare the pattern of brain [F] FDG uptake in suspected non-Alzheimer's pathophysiology (SNAP), AD, and healthy controls using 2-deoxy-2-[F]fluoroglucose ([F] FDG) positron emission tomography imaging. Cerebrospinal fluid (CSF) biomarkers amyloid-β1-42 peptide (Aβ1-42) and tau were used in order to differentiate AD from SNAP.

The Retina as a Window or Mirror of the Brain Changes Detected in Alzheimer's Disease: Critical Aspects to Unravel.

Alzheimer's disease is the most frequent cause of dementia worldwide, representing a global health challenge, with a massive impact on the quality of life of Alzheimer's disease patients and their relatives. The diagnosis of Alzheimer's disease constitutes a real challenge, because the symptoms manifest years after the first degenerative changes occurring in the brain and the diagnosis is based on invasive and/or expensive techniques. Therefore, there is an urgent need to identify new reliable biomarkers to...

Protective effects of melatonin on mitochondrial biogenesis and mitochondrial structure and function in the HEK293-APPswe cell model of Alzheimer's disease.

The effects and mechanisms of melatonin on Alzheimer's disease (AD) are still not researched thoroughly. 20E2 cells (HEK293-APPswe cells) are a cellular model of AD. The modulation effects of melatonin on the structure and function of mitochondria in 20E2 cells need to be studied.

Identification of the Structure of a Probabilistic Boolean Network From Samples Including Frequencies of Outcomes.

We study the problem of identifying the structure of a probabilistic Boolean network (PBN), a probabilistic model of biological networks, from a given set of samples. This problem can be regarded as an identification of a set of Boolean functions from samples. Existing studies on the identification of the structure of a PBN only use information on the occurrences of samples. In this paper, we also make use of the frequencies of occurrences of subtuples, information that is obtainable from the samples. We sh...

Performing an In Silico Repurposing of Existing Drugs by Combining Virtual Screening and Molecular Dynamics Simulation.

Drug repurposing has become one of the most widely used methods that can make drug discovery more efficient and less expensive. Additionally, computational methods such as structure-based drug designing can be utilized to make drug discovery more efficient and more accurate. Now imagine what can be achieved by combining drug repurposing and computational methods together in drug discovery, "in silico repurposing." In this chapter, we tried to describe a method that combines structure-based virtual screening...

A Computational Bipartite Graph-Based Drug Repurposing Method.

We present a bipartite graph-based approach to calculate drug pairwise similarity for identifying potential new indications of approved drugs. Both chemical and molecular features were used in drug similarity calculation. In this paper, we first extracted drug chemical structures and drug-target interactions. Second, we computed chemical structure similarity and drug- target profile similarity. Further, we constructed a bipartite graph model with known relationships between drugs and their target proteins. ...

Pseudopeptide Designed to Inhibit Oligomerization and Redox Chemistry in Alzheimer's Disease.

Aggregation of amyloid beta peptide (Aβ) and inflammatory processes associated with the generation of superoxide, hydrogen peroxide and hydroxyl radicals are responsible for neurotoxicity in Alzheimer's disease. The latter are a result of the redox activity of copper-bound Aβ complexes with molecular oxygen. A ligand (PI1), previously designed to compete with Aβ for copper, and a pseudopeptide (SGC1) with a property of breaking the self aggregation of Aβ, are attached to each other to form a new pseudop...

Sitagliptin protects the cognition function of the Alzheimer's disease mice through activating glucagon-like peptide-1 and BDNF-TrkB signalings.

Sitagliptin is an anti-diabetic drug and its effects on Alzheimer's disease (AD) remain controversial. This study aimed to investigate the protective effect of sitagliptin on the cognition in AD and its underlying molecular mechanism.

Failure to detect an association between self-reported traumatic brain injury and Alzheimer's disease neuropathology and dementia.

Recent research with neuropathologic or biomarker evidence of Alzheimer's disease (AD) casts doubt on traumatic brain injury (TBI) as a risk factor for AD. We leveraged the National Alzheimer's Coordinating Center to examine the association between self-reported TBI with loss of consciousness and AD neuropathologic changes, and with baseline and longitudinal clinical status.

Polycomb Repressive 2 Complex-Molecular Mechanisms of Function.

Numerous molecular processes conduct epigenetic regulation of protein transcription to maintain cell specification. In this review, we discuss molecular mechanisms of the Polycomb group (PcG) of proteins and its enzymatic role in epigenetics. More specifically, we focus on the Polycomb repressive complex 2 (PRC2) and the effects of its repressive marker. We have compiled information regarding the biological structure and how that impacts the stability of the complex. In addition, we examined functions of th...

The Alz-tau Biomarker for Alzheimer's Disease: Study in a Caucasian Population.

The establishment of a molecular biomarker for early detection of Alzheimer's disease (AD) is critical for diagnosis and follow up of patients, and as a quantitative parameter in the evaluation of potential new drugs to control AD. A list of blood biomarkers has been reported but none has been validated for the Alzheimer's clinic. The changes in hyperphosphorylated tau and amyloid peptide in the cerebrospinal fluid is currently used as a tool in the clinics and for research purposes, but this method is high...

Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer's Disease Subjects.

Amyloid plaque and tau-containing neurofibrillary tangles are important features of Alzheimer's disease (AD). However, the relationship between these processes is still debated.

Causal reasoning on Boolean control networks based on abduction: theory and application to Cancer drug discovery.

Complex diseases such as Cancer or Alzheimer's are caused by multiple molecular perturbations leading to pathological cellular behavior. However, the identification of the disease-induced molecular perturbations and the subsequent development of efficient therapies are challenged by the complexity of the genotype-phenotype relationship. Accordingly, a key issue is to develop frameworks relating the molecular perturbations and drug effects to their consequences on cellular phenotypes. Such framework aims at ...


Advertisement
Quick Search
Advertisement
Advertisement